{"id":"votrient","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[{"effect":"Diarrhea","drugRate":"","severity":"common","organSystem":""},{"effect":"Hypertension","drugRate":"","severity":"common","organSystem":""},{"effect":"Hair color change","drugRate":"","severity":"common","organSystem":""},{"effect":"Nausea","drugRate":"","severity":"common","organSystem":""},{"effect":"Fatigue","drugRate":"","severity":"common","organSystem":""},{"effect":"Anorexia","drugRate":"","severity":"common","organSystem":""},{"effect":"Vomiting","drugRate":"","severity":"common","organSystem":""},{"effect":"Decreased weight","drugRate":"","severity":"common","organSystem":""},{"effect":"Decreased appetite","drugRate":"","severity":"common","organSystem":""},{"effect":"Tumor pain","drugRate":"","severity":"common","organSystem":""},{"effect":"Musculoskeletal pain","drugRate":"","severity":"common","organSystem":""},{"effect":"Headache","drugRate":"","severity":"common","organSystem":""},{"effect":"Dysgeusia","drugRate":"","severity":"common","organSystem":""},{"effect":"Dyspnea","drugRate":"","severity":"common","organSystem":""},{"effect":"Skin hypopigmentation","drugRate":"","severity":"common","organSystem":""},{"effect":"Weight decreased","drugRate":"9%","severity":"common","organSystem":""},{"effect":"Proteinuria","drugRate":"9%","severity":"common","organSystem":""},{"effect":"Alopecia","drugRate":"8%","severity":"common","organSystem":""},{"effect":"Rash","drugRate":"8%","severity":"common","organSystem":""},{"effect":"Palmar-plantar erythrodysesthesia","drugRate":"6%","severity":"common","organSystem":""}],"contraindications":["Acute Thromboembolic Stroke","Acute hemorrhage","Angina pectoris","Cardiovascular event risk","Cerebral hemorrhage","Congenital long QT syndrome","Diarrhea","Drug-induced hepatitis","Gastrointestinal fistula","Gastrointestinal hemorrhage","Gastrointestinal perforation","Hepatic failure","Hyperbilirubinemia","Hypertensive disorder","Hypertensive urgency","Hypocalcemia","Hypokalemia","Hypomagnesemia","Hypothyroidism","Impaired wound healing","Liver function tests abnormal","Myocardial infarction","Pancreatitis","Pregnancy, function","Prolonged QT interval","Proteinuria","Surgical procedure","Thromboembolic disorder","Torsades de pointes","UGT1A1*28 polymorphism"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[{"effect":"Left ventricular dysfunction","drugRate":"8%","severity":"serious"},{"effect":"Hypothyroidism","drugRate":"8%","severity":"serious"},{"effect":"Elevated lipase (Grade 3-4)","drugRate":"3.1%","severity":"serious"},{"effect":"Chest pain","drugRate":"5%","severity":"serious"},{"effect":"Facial edema","drugRate":"1%","severity":"serious"}]},"trials":[],"_chembl":null,"aliases":["pazopanib"],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Votrient","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T02:05:38.232236+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T02:05:43.612136+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Votrient","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T02:05:44.313629+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Fibroblast growth factor receptor 1 inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T02:05:45.363611+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201733/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T02:05:45.018314+00:00"}},"offLabel":[],"timeline":[],"_dailymed":{"setId":"eeaaaf38-fb86-4d9f-a19d-0f61daac2fd7","title":"VOTRIENT (PAZOPANIB HYDROCHLORIDE) TABLET, FILM COATED [NOVARTIS PHARMACEUTICALS CORPORATION]"},"ecosystem":[],"mechanism":{"target":"Bone morphogenetic protein receptor type-1B, Cyclin-dependent kinase 11A, Cyclin-dependent kinase 11B"},"_scrapedAt":"2026-03-28T01:40:52.222Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T02:05:46.584605+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"Renal cell carcinoma","diseaseId":"renal-cell-carcinoma","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Sarcoma of soft tissue","diseaseId":"sarcoma-of-soft-tissue","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT02180867","phase":"PHASE2, PHASE3","title":"Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-07-11","conditions":"Alveolar Soft Part Sarcoma, Angiomatoid Fibrous Histiocytoma, Atypical Fibroxanthoma","enrollment":140},{"nctId":"NCT01552356","phase":"PHASE1","title":"Pazopanib Hydrochloride in Treating Patients With Advanced or Refractory Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2012-03-19","conditions":"Solid Neoplasm","enrollment":54},{"nctId":"NCT01575548","phase":"PHASE3","title":"Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2012-08-08","conditions":"Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v7","enrollment":129},{"nctId":"NCT01841736","phase":"PHASE2","title":"Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2013-09-20","conditions":"Foregut Neuroendocrine Tumor, Hindgut Neuroendocrine Tumor, Metastatic Digestive System Neuroendocrine Tumor G1","enrollment":171},{"nctId":"NCT05700461","phase":"PHASE1","title":"Drug Screening Using Novel IMD in Renal Cell Carcinoma","status":"ENROLLING_BY_INVITATION","sponsor":"Oliver Jonas","startDate":"2024-12-01","conditions":"Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Kidney Cancer","enrollment":20},{"nctId":"NCT03850964","phase":"PHASE2, PHASE3","title":"Effects of Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia (Paz)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cure HHT","startDate":"2023-05-08","conditions":"Hereditary Hemorrhagic Telangiectasia, Epistaxis, Anemia","enrollment":70},{"nctId":"NCT07444619","phase":"PHASE1","title":"A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue Sarcomas","status":"NOT_YET_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2026-08-31","conditions":"Soft Tissue Sarcomas","enrollment":18},{"nctId":"NCT01684397","phase":"PHASE1, PHASE2","title":"Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2012-11-21","conditions":"Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer","enrollment":51},{"nctId":"NCT02645149","phase":"PHASE2","title":"Molecular Profiling and Matched Targeted Therapy for Patients With Unresectable Advanced or Metastatic Melanoma","status":"COMPLETED","sponsor":"Melanoma Institute Australia","startDate":"2021-11-22","conditions":"Melanoma","enrollment":216},{"nctId":"NCT02184416","phase":"","title":"Study Of The Impact Of Inlyta In 2nd Line On The Treatment Outcomes Of mRCC Patients Treated With Sutent In 1st Line In The Real Life Setting","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-10-31","conditions":"Metastatic Renal Cell Carcinoma (mRCC)","enrollment":554},{"nctId":"NCT04199026","phase":"NA","title":"Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-02-25","conditions":"Metastatic Sarcoma, Recurrent Sarcoma, Resectable Sarcoma","enrollment":20},{"nctId":"NCT05180695","phase":"PHASE1, PHASE2","title":"HDM201 and Pazopanib in Patients With P53 Wild-type Advanced/Metastatic Soft Tissue Sarcomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Leon Berard","startDate":"2022-04-15","conditions":"Advanced Soft-tissue Sarcoma, Metastatic Soft-tissue Sarcoma","enrollment":47},{"nctId":"NCT05432791","phase":"PHASE2, PHASE3","title":"Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-03-30","conditions":"Locally Advanced Uterine Corpus Leiomyosarcoma, Metastatic Uterine Corpus Leiomyosarcoma, Stage III Uterine Corpus Leiomyosarcoma AJCC v8","enrollment":73},{"nctId":"NCT01217931","phase":"PHASE2","title":"Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2011-01-19","conditions":"Kidney Cancer","enrollment":180},{"nctId":"NCT06239272","phase":"PHASE1, PHASE2","title":"NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2024-03-27","conditions":"Adipocytic Neoplasm, Liposarcoma, Atypical Fibroxanthoma","enrollment":139},{"nctId":"NCT05210413","phase":"PHASE1, PHASE2","title":"Spartalizumab and Low-dose PAzopanib in Refractory or Relapsed Solid TumOrs of Pediatric and Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital, Bordeaux","startDate":"2022-05-17","conditions":"Refractory or Recurrent Solid Tumor","enrollment":80},{"nctId":"NCT06726421","phase":"PHASE3","title":"Systemic Therapy Alone or With Stereotactic Body Radiotherapy for Oligometastatic Kidney Cancer (STROKER Study)","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-09-18","conditions":"Renal Cell Carcinoma (Kidney Cancer), Kidney Cancer Metastatic, Renal Cell Carcinoma Metastatic","enrollment":252},{"nctId":"NCT01876082","phase":"PHASE2","title":"PAZOPANIB Efficacy and Tolerance in Desmoids Tumors","status":"COMPLETED","sponsor":"Institut Bergonié","startDate":"2012-09-18","conditions":"Progressive Desmoids Tumors","enrollment":72},{"nctId":"NCT01931098","phase":"PHASE2","title":"Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2015-12-10","conditions":"Glioblastoma, Glioblastoma Multiforme, Gliosarcoma","enrollment":35},{"nctId":"NCT02029001","phase":"PHASE2","title":"Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment","status":"RECRUITING","sponsor":"Centre Leon Berard","startDate":"2014-03","conditions":"Malignant Solid Neoplasms","enrollment":900},{"nctId":"NCT01582204","phase":"NA","title":"Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2012-04","conditions":"Renal Cancer","enrollment":17},{"nctId":"NCT06263231","phase":"PHASE3","title":"A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Intensity Therapeutics, Inc.","startDate":"2024-06-28","conditions":"Sarcoma,Soft Tissue","enrollment":333},{"nctId":"NCT03260894","phase":"PHASE3","title":"Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2017-12-07","conditions":"Renal Cell Carcinoma (RCC)","enrollment":129},{"nctId":"NCT02956798","phase":"PHASE2","title":"SAbR For Oligometastatic Renal Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2018-07-19","conditions":"Oligometastatic Renal Cell Carcinoma","enrollment":23},{"nctId":"NCT07087158","phase":"PHASE2","title":"A Study of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Imbioray (Hangzhou) Biomedicine Co., Ltd.","startDate":"2025-08-10","conditions":"Renal Cell Carcinoma (RCC)","enrollment":30},{"nctId":"NCT05679921","phase":"PHASE2","title":"Pazopanib With or Without Pembrolizumab for Metastatic Soft Tissue Sarcoma","status":"RECRUITING","sponsor":"Yonsei University","startDate":"2024-03-01","conditions":"Soft Tissue Sarcoma","enrollment":116},{"nctId":"NCT02331498","phase":"PHASE1, PHASE2","title":"Phase I/II Study of Pazopanib+ Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme","status":"RECRUITING","sponsor":"Centre Antoine Lacassagne","startDate":"2015-06","conditions":"Glioblastoma Multiforme","enrollment":51},{"nctId":"NCT01436227","phase":"PHASE2","title":"Pazopanib Hydrochloride in Treating Patients With Von Hippel-Lindau Syndrome","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-01-17","conditions":"Von Hippel-Lindau Syndrome","enrollment":32},{"nctId":"NCT03660930","phase":"PHASE1, PHASE2","title":"Nab-Sirolimus and Pazopanib Hydrochloride in Treating Patients With Advanced Nonadipocytic Soft Tissue Sarcomas","status":"TERMINATED","sponsor":"University of Washington","startDate":"2019-04-01","conditions":"Advanced Soft Tissue Sarcoma, Locally Advanced Soft Tissue Sarcoma, Metastatic Soft Tissue Sarcoma","enrollment":19},{"nctId":"NCT03592472","phase":"PHASE3","title":"A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)","status":"RECRUITING","sponsor":"Xynomic Pharmaceuticals, Inc.","startDate":"2018-07-17","conditions":"Renal Cell Carcinoma","enrollment":413},{"nctId":"NCT00720941","phase":"PHASE3","title":"Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-08-14","conditions":"Carcinoma, Renal Cell","enrollment":1110},{"nctId":"NCT01147822","phase":"PHASE2","title":"Pazopanib Versus Sunitinib in the Treatment of Asian Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-05-19","conditions":"Carcinoma, Renal Cell","enrollment":367},{"nctId":"NCT06895733","phase":"PHASE1, PHASE2","title":"Study of Pazopanib Combined With Palbociclib for Refractory Solid Tumors With Co-amplified in the 11q13(FGF3/4/19/CCND1)","status":"RECRUITING","sponsor":"Tianjin Medical University Second Hospital","startDate":"2024-11-27","conditions":"Solid Tumor, Adult, Next-generation Sequencing, Precision Medicine","enrollment":65},{"nctId":"NCT01543763","phase":"PHASE1","title":"Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors","status":"COMPLETED","sponsor":"Pamela Munster","startDate":"2012-06-25","conditions":"Metastatic Solid Tumors","enrollment":90},{"nctId":"NCT04659343","phase":"","title":"TDM for Optimized Outcome in Patients With mRCC.","status":"RECRUITING","sponsor":"Niels Fristrup","startDate":"2020-11-01","conditions":"Kidney Cancer, Renal Cell Carcinoma Metastatic, Drug Toxicity","enrollment":200},{"nctId":"NCT01767636","phase":"PHASE2","title":"Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2013-05-16","conditions":"Carcinoma of the Collecting Ducts of Bellini, Chromophobe Renal Cell Carcinoma, Kidney Medullary Carcinoma","enrollment":38},{"nctId":"NCT04823923","phase":"NA","title":"Impact of Chronic Renal Failure on Plasma Exposure of Kinase Inhibitors in Patients Treated for Metastatic Kidney Cancer","status":"RECRUITING","sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","startDate":"2021-12-06","conditions":"Kidney Neoplasm","enrollment":60},{"nctId":"NCT06816771","phase":"PHASE2","title":"Evaluation of the Efficacy and Safety of Pazopanib in Combination with TGI/CIV for Recurrent or Refractory Rhabdomyosarcoma in Children or Adolescents","status":"RECRUITING","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2025-02","conditions":"Rhabdomyosarcoma, Recurrent, Refractory","enrollment":38},{"nctId":"NCT06739395","phase":"PHASE2","title":"Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion","status":"RECRUITING","sponsor":"Tianjin Medical University Second Hospital","startDate":"2024-11-01","conditions":"Solid Tumor, Precision Medicine","enrollment":300},{"nctId":"NCT02203760","phase":"PHASE2","title":"Pazopanib Vs. Pazopanib Plus Gemcitabine","status":"ACTIVE_NOT_RECRUITING","sponsor":"North Eastern German Society of Gynaecological Oncology","startDate":"2019-10-16","conditions":"Leiomyosarcoma or Carcinosarcoma","enrollment":58},{"nctId":"NCT02009449","phase":"PHASE1","title":"A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2013-11-15","conditions":"Melanoma, Prostate Cancer, Ovarian Cancer","enrollment":353},{"nctId":"NCT05363072","phase":"","title":"A Study to Describe the Kidney Cancer Patient Population Treatment, and Results in the Hospital District of Southwest Finland.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-05-02","conditions":"Renal Cell Cancer, Renal Cell Carcinoma, Cancer of Kidney","enrollment":1112},{"nctId":"NCT02207309","phase":"PHASE2","title":"Pazopanib Maintenance Phase II","status":"TERMINATED","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2015-06-22","conditions":"Sarcoma","enrollment":1},{"nctId":"NCT02049905","phase":"PHASE3","title":"Phase 3 Study to Treat Patients With Soft Tissue Sarcomas","status":"COMPLETED","sponsor":"ImmunityBio, Inc.","startDate":"2014-01","conditions":"Metastatic, Locally Advanced or Unresectable Soft Tissue Sarcoma","enrollment":433},{"nctId":"NCT01402271","phase":"PHASE1, PHASE2","title":"Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer","status":"COMPLETED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2012-07","conditions":"Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer","enrollment":88},{"nctId":"NCT05949424","phase":"PHASE4","title":"OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults","status":"UNKNOWN","sponsor":"University Medical Center Groningen","startDate":"2024-05","conditions":"Renal Cell Carcinoma, Ovarian Carcinoma, Thyroid Carcinoma","enrollment":30},{"nctId":"NCT00827372","phase":"PHASE2","title":"A Study of Vascular Endothelial Growth Factor (VEGF) Inhibition in Patients With Unilateral Upper Extremity Lymphedema Following Treatment for Cancer","status":"COMPLETED","sponsor":"Kathy Miller","startDate":"2009-01","conditions":"Lymphedema","enrollment":10},{"nctId":"NCT02383251","phase":"PHASE2","title":"Paclitaxel/Pazopanib for Platinum Resistant/Refractory Ovarian Cancer","status":"COMPLETED","sponsor":"ARCAGY/ GINECO GROUP","startDate":"2015-06-15","conditions":"Ovarian Cancer","enrollment":118},{"nctId":"NCT04741438","phase":"PHASE3","title":"Efficacy of the Combination of Nivolumab and Ipilimumab as a Treatment in Patients With Sarcoma of Rare Subtype","status":"UNKNOWN","sponsor":"Centre Leon Berard","startDate":"2021-03-30","conditions":"Sarcoma","enrollment":96},{"nctId":"NCT03200717","phase":"PHASE2","title":"Study of Efficacy, Safety, and Quality of Life of Pazopanib in Patients With Advanced and/or Metastatic Renal Cell Carcinoma After Prior Checkpoint Inhibitor Treatment","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-11-14","conditions":"Advanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma","enrollment":62},{"nctId":"NCT03798106","phase":"PHASE2","title":"A Study of Pazopanib and Durvalumab for Metastatic Soft Tissue Sarcoma","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2019-04-10","conditions":"Sarcoma","enrollment":46},{"nctId":"NCT01430572","phase":"PHASE1","title":"Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2011-10-07","conditions":"Advanced Cancers, Solid Tumors","enrollment":62},{"nctId":"NCT05816642","phase":"NA","title":"Application Circulating Tumor DNA Dynamic Monitoring in Clinical Treatment of Metastatic Renal Cell Carcinoma","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2022-08-01","conditions":"Metastatic Renal Cell Carcinoma","enrollment":500},{"nctId":"NCT02066285","phase":"PHASE2","title":"Trial of Pazopanib in Patients With Solitary Fibrous Tumor and Extraskeletal Myxoid Chondrosarcoma","status":"COMPLETED","sponsor":"Grupo Espanol de Investigacion en Sarcomas","startDate":"2014-06","conditions":"Solitary Fibrous Tumor, Extraskeletal Myxoid Chondrosarcoma","enrollment":96},{"nctId":"NCT02776644","phase":"","title":"Clinical Outcome Of Advanced Renal Cell Carcinoma In Taiwan","status":"COMPLETED","sponsor":"Pfizer","startDate":"2016-10-15","conditions":"Renal Cell Carcinoma","enrollment":1349},{"nctId":"NCT01330966","phase":"PHASE2","title":"Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma","status":"COMPLETED","sponsor":"Emerald Clinical Inc.","startDate":"2011-04","conditions":"Chondrosarcoma, Metastatic Chondrosarcoma","enrollment":47},{"nctId":"NCT01407562","phase":"PHASE1","title":"Study of Pazopanib, Paclitaxel, and Carboplatin in Patients With Advanced Solid Tumors","status":"TERMINATED","sponsor":"Rutgers, The State University of New Jersey","startDate":"2010-09-17","conditions":"Unspecified Adult Solid Tumor - Protocol Specific, Breast Cancer - Female","enrollment":34},{"nctId":"NCT03850730","phase":"PHASE1, PHASE2","title":"Pazopanib for the Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia","status":"UNKNOWN","sponsor":"Cure HHT","startDate":"2023-07-01","conditions":"Hereditary Hemorrhagic Telangiectasia, Epistaxis","enrollment":30},{"nctId":"NCT02601209","phase":"PHASE1, PHASE2","title":"Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2015-11-30","conditions":"High Grade Sarcoma, Metastatic Leiomyosarcoma, Metastatic Malignant Peripheral Nerve Sheath Tumor","enrollment":151},{"nctId":"NCT01462630","phase":"PHASE2","title":"Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma","status":"COMPLETED","sponsor":"Fox Chase Cancer Center","startDate":"2011-11-03","conditions":"Adult Angiosarcoma, Recurrent Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma","enrollment":29},{"nctId":"NCT01236547","phase":"PHASE2","title":"Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-10-28","conditions":"Thyroid Gland Anaplastic Carcinoma","enrollment":123},{"nctId":"NCT01468922","phase":"PHASE1","title":"Pazopanib and ARQ 197 for Advanced Solid Tumors","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2012-01-23","conditions":"Solid Tumor","enrollment":32},{"nctId":"NCT02551718","phase":"NA","title":"High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia","status":"COMPLETED","sponsor":"University of Washington","startDate":"2015-09-11","conditions":"Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia","enrollment":34},{"nctId":"NCT02303028","phase":"PHASE1, PHASE2","title":"Phase I Dose Escalation Study of Topotecan and Pazopanib in Children With Recurrent/Refractory Solid Tumours","status":"COMPLETED","sponsor":"The Hospital for Sick Children","startDate":"2015-03","conditions":"Solid Tumors","enrollment":30},{"nctId":"NCT02691767","phase":"NA","title":"Study to Evaluate the Safety and Efficacy of Pazopanib, in Subject With Refractory Solid Tumors","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2016-05","conditions":"Refractory Solid Tumors","enrollment":2},{"nctId":"NCT02450136","phase":"NA","title":"Single-arm Study to Evaluate the Safety and Efficacy of Pazopanib, in Subjects With FGFR2 Amplification, FGFR2 Mutation Refractory Solid Tumors","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2015-10-08","conditions":"Refractory Solid Tumors","enrollment":2},{"nctId":"NCT01498458","phase":"PHASE1","title":"Pazopanib in Combination With Capecitabine in Patients With Metastatic Breast Cancer","status":"COMPLETED","sponsor":"GBG Forschungs GmbH","startDate":"2010-10","conditions":"Metastatic Breast Cancer","enrollment":9},{"nctId":"NCT01157091","phase":"PHASE2","title":"Pazopanib Hydrochloride in Treating Patients With Stage IV Kidney Cancer","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2010-12-08","conditions":"Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage IV Renal Cell Cancer","enrollment":28},{"nctId":"NCT01664182","phase":"PHASE2","title":"Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2012-08-01","conditions":"Advanced Renal Cell Carcinoma, Advanced Sarcomatoid Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v7","enrollment":41},{"nctId":"NCT02357810","phase":"PHASE2","title":"Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2015-03-21","conditions":"Adult Liposarcoma, Metastatic Liposarcoma, Metastatic Osteosarcoma","enrollment":178},{"nctId":"NCT03334409","phase":"PHASE2","title":"Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed by Surgery","status":"TERMINATED","sponsor":"Academic and Community Cancer Research United","startDate":"2018-02-16","conditions":"Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8","enrollment":5},{"nctId":"NCT02212015","phase":"PHASE2","title":"Evaluation of Votrient in Angiosarcoma","status":"TERMINATED","sponsor":"Heidelberg University","startDate":"2014-07","conditions":"Angiosarcoma","enrollment":26},{"nctId":"NCT03628859","phase":"","title":"BIOREN (Predictive BIOmarkers in Metastatic RENal Cancer)","status":"UNKNOWN","sponsor":"Centre Leon Berard","startDate":"2018-12-21","conditions":"Renal Cancer Metastatic","enrollment":30},{"nctId":"NCT01513187","phase":"PHASE1, PHASE2","title":"Pazopanib in Combination With Interferon Alfa 2-A, in Patients With Advanced Renal Cell Carcinoma","status":"COMPLETED","sponsor":"Spanish Oncology Genito-Urinary Group","startDate":"2011-07-11","conditions":"Advanced Renal Cell Carcinoma","enrollment":53},{"nctId":"NCT01566747","phase":"PHASE2","title":"Second-line Pazopanib Renal Cell Carcinoma (RCC) Study. CTRIAL-IE (ICORG) 10-01, V5","status":"COMPLETED","sponsor":"Cancer Trials Ireland","startDate":"2011-03","conditions":"Renal Cell Carcinoma","enrollment":43},{"nctId":"NCT01472081","phase":"PHASE1","title":"Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2012-02-09","conditions":"Renal Cell Carcinoma, Clear-cell Metastatic Renal Cell Carcinoma","enrollment":194},{"nctId":"NCT01035658","phase":"PHASE1, PHASE2","title":"Pazopanib/Doxil in Adv Relapsed Plat Sensitive or Resistant Ovarian, Fallopian or Primary Peritoneal Adenocarcinoma","status":"TERMINATED","sponsor":"SCRI Development Innovations, LLC","startDate":"2010-01","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Carcinoma","enrollment":22},{"nctId":"NCT01532687","phase":"PHASE2","title":"Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma","status":"COMPLETED","sponsor":"OHSU Knight Cancer Institute","startDate":"2012-03-13","conditions":"Adult Alveolar Soft Part Sarcoma, Adult Angiosarcoma, Adult Desmoplastic Small Round Cell Tumor","enrollment":54},{"nctId":"NCT03735758","phase":"PHASE4","title":"Quality of Life in Patients With Non-adipocyte Soft Tissue Sarcoma Under Palliative Chemotherapy or Pazopanib","status":"TERMINATED","sponsor":"GWT-TUD GmbH","startDate":"2018-11-02","conditions":"Soft Tissue Sarcoma Adult","enrollment":11},{"nctId":"NCT01392183","phase":"PHASE2","title":"Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-10-24","conditions":"Kidney Cancer","enrollment":69},{"nctId":"NCT01548144","phase":"PHASE1","title":"Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-04","conditions":"Advanced Cancers","enrollment":178},{"nctId":"NCT02959554","phase":"PHASE2","title":"Study in Which Therapy is Either Switched to Nivolumab After 3 Months of Treatment or Therapy is Continued With a Tyrosine Kinase Inhibitor in Patients With Metastatic Renal Cell Carcinoma (RCC) and Disease Control","status":"TERMINATED","sponsor":"AIO-Studien-gGmbH","startDate":"2016-12","conditions":"Metastatic Renal Cell Carcinoma","enrollment":49},{"nctId":"NCT01465659","phase":"PHASE1, PHASE2","title":"Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2011-12-12","conditions":"Pancreatic Alpha Cell Carcinoma, Pancreatic Beta Islet Cell Carcinoma, Pancreatic Delta Cell Carcinoma","enrollment":29},{"nctId":"NCT02055690","phase":"PHASE1, PHASE2","title":"PAZOFOS: Phase Ib and Phase II Trial of Pazopanib +/- Fosbretabulin in Advanced Recurrent Ovarian Cancer","status":"TERMINATED","sponsor":"The Christie NHS Foundation Trust","startDate":"2014-09","conditions":"Ovarian Neoplasms, Neoplasms, Ovarian, Ovarian Cancer","enrollment":21},{"nctId":"NCT01743482","phase":"PHASE2","title":"Pazopanib in Advanced and Cisplatin-resistant Germ Cell Tumors","status":"COMPLETED","sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","startDate":"2013-05-17","conditions":"Germ Cell Tumors, Measurable Disease","enrollment":43},{"nctId":"NCT02960906","phase":"PHASE2","title":"A BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naïve Metastatic Kidney Cancer","status":"COMPLETED","sponsor":"Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie","startDate":"2017-05-31","conditions":"Clear Cell Metastatic Renal Cell Carcinoma","enrollment":200},{"nctId":"NCT01636908","phase":"NA","title":"Determination of Intratumoral Concentrations of Kinase Inhibitors in Patients With Advanced Solid Malignancies.","status":"COMPLETED","sponsor":"Amsterdam UMC, location VUmc","startDate":"2011-08","conditions":"Cancer, Advanced Solid Tumors","enrollment":43},{"nctId":"NCT01759303","phase":"PHASE2","title":"Study of Pazopanib in the Treatment of Osteosarcoma Metastatic to the Lung","status":"TERMINATED","sponsor":"Emerald Clinical Inc.","startDate":"2013-04","conditions":"Osteosarcoma, Metastatic Osteosarcoma","enrollment":12},{"nctId":"NCT01361334","phase":"PHASE2","title":"Pilot Clinical Trial of Pazopanib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or at Initial Diagnosis When no Intensive Treatment is Possible","status":"COMPLETED","sponsor":"University Hospital Muenster","startDate":"2011-06","conditions":"Acute Myeloid Leukemia","enrollment":20},{"nctId":"NCT02570789","phase":"PHASE4","title":"Evaluation of Predictive Markers for Toxicity and Efficacy in Patients With mccRCC Treated by Anti-VEGF Therapy","status":"TERMINATED","sponsor":"Cliniques universitaires Saint-Luc- Université Catholique de Louvain","startDate":"2012-12","conditions":"Clear-cell Metastatic Renal Cell Carcinoma","enrollment":90},{"nctId":"NCT01610206","phase":"PHASE2","title":"A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cancer","status":"COMPLETED","sponsor":"Linda R Duska","startDate":"2012-09","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer","enrollment":148},{"nctId":"NCT00866697","phase":"PHASE3","title":"Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-05-26","conditions":"Ovarian Cancer","enrollment":940},{"nctId":"NCT02354612","phase":"","title":"Open Label Continuation Study of TRC105 for Patients Who Have Completed a Prior TRC105 Trial","status":"NO_LONGER_AVAILABLE","sponsor":"Tracon Pharmaceuticals Inc.","startDate":"","conditions":"Solid Tumors","enrollment":""},{"nctId":"NCT01543802","phase":"PHASE2","title":"Study of Preoperative Therapy With Pazopanib (Votrient®) to Treat High-risk Soft Tissue Sarcoma","status":"TERMINATED","sponsor":"Heidelberg University","startDate":"2013-04","conditions":"Sarcoma, Soft-tissue","enrollment":21},{"nctId":"NCT02555748","phase":"PHASE4","title":"Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma","status":"COMPLETED","sponsor":"Institut Claudius Regaud","startDate":"2015-11-17","conditions":"Metastatic Renal Cell Cancer","enrollment":47},{"nctId":"NCT03139331","phase":"PHASE1","title":"PAZIT Study for Children and Young Adults With Relapsed or Refractory Sarcoma","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2017-06-06","conditions":"Sarcoma, Refractory Sarcoma","enrollment":16},{"nctId":"NCT01235962","phase":"PHASE3","title":"A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-11-30","conditions":"Renal Cell Carcinoma (RCC), Cancer","enrollment":1538},{"nctId":"NCT02071719","phase":"","title":"Prediction of Response to Kinase Inhibitors Based on Protein Phosphorylation Profiles in Tumor Tissue From Advanced Renal Cell Cancer Patients","status":"TERMINATED","sponsor":"M. Labots","startDate":"2012-04","conditions":"Renal Cell Cancer","enrollment":6},{"nctId":"NCT02788201","phase":"PHASE2","title":"Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-03-27","conditions":"Urothelial Carcinoma, Bladder Cancer, Urinary Bladder Neoplasms","enrollment":8},{"nctId":"NCT02138526","phase":"PHASE1","title":"Pazopanib Tolerability When Given With Food","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2014-06","conditions":"Cancer","enrollment":78}],"_emaApprovals":[],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"chemblId":"CHEMBL1201733"},"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":38,"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Votrient","genericName":"Votrient","companyName":"Tracon Pharmaceuticals Inc.","companyId":"tracon-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":11,"withResults":5},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T02:05:46.584605+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}